Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump Slams FDA Regulations In Joint Session Of Congress

Executive Summary

US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.

You may also be interested in...

Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments

State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.

FDA Soliciting Broad Range Of Comments From Industry On Regulatory Reform

FDA is addressing regulatory reform as part of President Trump's "two-for-one" executive order, and seeks industry comments to supplement the effort.

Can The FDA Climate Be Too Good?

US FDA’s decision to accept Amicus’ migalastat NDA without a new study is the latest sign of the positive climate for rare disease drugs at FDA. But will it be remembered as a turning point?

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts